# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Needham analyst Ami Fadia reiterates Cogent Biosciences (NASDAQ:COGT) with a Buy and maintains $18 price target.
Cogent Biosciences (NASDAQ:COGT) reported quarterly losses of $(0.62) per share which missed the analyst consensus estimate of ...
U.S. stock futures were higher this morning, with the Dow futures gaining over 200 points on Monday.
JP Morgan analyst Anupam Rama maintains Cogent Biosciences (NASDAQ:COGT) with a Overweight and raises the price target from ...
Citigroup analyst David Lebowitz maintains Cogent Biosciences (NASDAQ:COGT) with a Buy and raises the price target from $11 ...
Cogent Biosciences (NASDAQ:COGT) reported quarterly losses of $(0.63) per share. This is a 12.5 percent decrease over losses of...
Needham analyst Ami Fadia reiterates Cogent Biosciences (NASDAQ:COGT) with a Buy and maintains $18 price target.